Kimura K, Nagasaka T, Hoshizima N, Sasamoto H, Notohara K, Takeda M, Kominami K, Iishii T, Tanaka N, Matsubara N
Department of Gastroenterological Surgery and Surgical Oncology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan.
J Int Med Res. 2007 Jul-Aug;35(4):450-7. doi: 10.1177/147323000703500403.
Codon 12 and 13 mutations in 170 colorectal cancer (CRC) and 66 gastric cancer (GC) specimens were analysed by an 'enriched' polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. All identified mutations were verified by direct sequencing of the second PCR products. Among the 170 CRC specimens, mutations were identified in 47 (28%) and 13 (7.6%) cases in codons 12 and 13, respectively. In the 66 GC specimens examined, however, mutations in codons 12 and 13 were only detected in two (3.0%) and one (1.5%) cases, respectively. Mutations in both codon 12 and 13 were found in 3/170 (1.8%) CRCs and 1/66 (1.5%) GCs. Duplicate mutations were never identified in the same allele, which was confirmed by direct sequencing of the second amplified products. The majority of colorectal and gastric cancer cells with KRAS mutations are homogeneous because they have the same KRAS mutation. A few colorectal or gastric cancers, however, showed heterogeneity, as verified by the fact that single mutations were identified in the same allele.
采用“富集”聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法,对170份结直肠癌(CRC)标本和66份胃癌(GC)标本中的密码子12和13突变进行了分析。所有鉴定出的突变均通过对第二轮PCR产物进行直接测序加以验证。在170份CRC标本中,密码子12和13的突变分别在47例(28%)和13例(7.6%)中被鉴定出来。然而,在检测的66份GC标本中,密码子12和13的突变分别仅在2例(3.0%)和1例(1.5%)中被检测到。在3/170(1.8%)的CRC和1/66(1.5%)的GC中发现了密码子12和13的双重突变。在同一个等位基因中从未鉴定出重复突变,这一点通过对第二轮扩增产物的直接测序得到了证实。大多数具有KRAS突变的结直肠癌和胃癌细胞是同质的,因为它们具有相同的KRAS突变。然而,少数结直肠癌或胃癌表现出异质性,这一点通过在同一个等位基因中鉴定出单一突变得到了证实。